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Mangiferin and mangiferin-containing extracts from Mangifera foedita leaves are potent candidates as antioxidant iron chelators 
in the management of iron-overloaded thalassemia patients and may help to lower the costs of their treatment. 
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Introduction: Thalassemia is a hereditary anemia usually treated with regular blood 
transfusions, which can result in elevated levels of total iron in the body. As soon as the 
capacity of iron-regulating proteins (e.g., ferritin, transferrin) are used up, free plasma iron 
increases generating reactive oxygen species (ROS), leading to oxidative stress. Hence, blood 
transfusions should be accompanied by iron-chelating therapy, e.g., deferiprone (DFP). The 
purpose of this study was to evaluate the effect of mangiferin (M) and an aqueous leaf extract 
of Mangifera foetida L (EMF) as alternative iron-chelating antioxidants in an animal model. 
Methods: Thirty male Sprague Dawley rats were randomly divided into 5 equal groups: 
normal control, iron overload (IO), IO+DFP, IO+M, and IO+EMF. Iron overload was induced 
by intraperitoneal iron dextran injection with a total dose of 90 mg/mouse (15 mg Fe/mouse 
every 3-4 days for 3 weeks) followed by oral administration of DFP 462.5 mg/kg, mangiferin 
75 mg/kg, or EMF 2.930 g/kg for 7 days. 
Results: Body weight (BW) increased in all groups during the 4 weeks of experiment, except 
for the IO group. As expected, DFP decreased significantly the total plasma iron and increased 
iron excretion via urine in iron-overloaded rats (positive control), mangiferin and EMF had 
similar – although slightly smaller – effects than DFP. The antioxidant activity of M and 
EMF were stronger compared to DFP as determined by plasma superoxide dismutase (SOD) 
activity. 
Conclusion: Mangiferin and EMF have iron-chelating and antioxidant effects and might be 
used for the treatment of iron overload in the body.
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A B S T R A C T
Introduction
Thalassemia is a hereditary hemolytic anemia resulting 
from the pathological synthesis of abnormal hemoglobin 
(1). The disease spreads from the Mediterranean via the 
Middle East and India to South-East Asia (2). In Indonesia, 
thalassemia is the most frequent single genetic disorder 
and a serious health problem due to the high morbidity 
and mortality of patients. The frequence of β-thalassemia 
gene and HbE in Indonesian carriers ranges between 
1%–33% (2). Clinically, thalassemia is divided into minor 
(or trait), intermedia and major ones (1,3). The clinical 
pictures of chronic anemia because erythropoiesis does 
not function well, intra- and extramedullary hemolysis 
occurs, and iron overload is present due to increased 
gastro-intestinal (GI) iron absorption and supply of blood 
transfusions (4).
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Iron overload is a long-term condition in which the 
body absorbs excessive amounts of iron into the blood 
from which it accumulates in body tissues, such as liver, 
heart and other organs (5). Iron overload can be dangerous 
as a progressive cause of irreversible organ damage before 
clinical symptoms develop (6,7).
Free iron can generate reactive oxygen species (ROS), 
which cause damage to tissues, especially to the liver and 
the heart (8-10). Excess iron in the body must be treated 
with iron chelators (11,12), e.g., deferoxamin (DFO) as 
one of the standard drugs. Besides the high price, DFO 
has serious side effects and a complicated invasive method 
of administration. Oral chelating agents have been 
developed and released to the market, such as deferiprone 
(DFP) and deferasirox, but the application of these drugs 
is still very limited because of their high price. Until now, 
the goal of treatment of iron overload due to repeated 
transfusions in patients with thalassemia can often not be 
reached because of price constraints.
During the last years, researches have been conducted 
for the development of alternative iron-chelating agents 
from natural sources in Indonesia, which are safer, less 
expensive, and readily available to Indonesian patients 
(13). One of these herbal candidates is mangiferin, a 
flavonoid extracted from various parts of Mangifera indica 
L., which was proven an antioxidant and iron chelator in 
vitro (14-17). The formula of mangiferin was presented by 
Pardo-Andreau et al (14). 
Soediro et al (18) found that among seven mango 
cultivars in Indonesia, the leaves of M. foetida L had the 
highest content in mangiferin. Purwaningsih et al (19) 
reported in an ex vivo study that 1.125 mg aqueous leaf 
extract of M. foetida had no significantly different iron-
chelating effect compared to 100 ug of purified mangiferin. 
This research was carried out with mangiferin-
containing aqueous leaf extract from M. foetida as iron 
chelation therapy and compared with DFP as the standard 
drug. Our model used mice, which was administered 
excessive iron resulting in experimental iron overload. 
The results are expected to be useful as iron chelation 
in patients with thalassemia for complementary and/or 
alternative therapy. The research data can also be used for 
testing the effectiveness and safety in the next phase or 
even in clinical trials.
Materials and Methods
Mangiferin and leaf extract from Mangifera foetida L
Purified mangiferin (content 95.8%) was obtained from 
extracts of leaves of Mangifera indica L (Plamed Science 
Technology Inc., China). Leaf extract from M. foetida 
(EMF) was prepared according to Wayuni et al (20). Leaves 
from M. foetida (Indonesian name Mangga bacang) from 
the Depok area, West Java, were identified by LIPI Kebun 
Raya Bogor (Botanical Garden Bogor, certificate 4565/
IPH.3/KS/X/2014).
Chemical analysis of the ethanolic EMF by Wayuni et al 
(20) showed no alkaloids (= negative Mayer-Bouchardat-
Dragendorf reactions), but presence of flavonoids and 
saponins (strong positive chemical reactions), as well as 
triterpenoids (positive Liebermann–Burchard reaction). 
Total flavonoid content was 1.035 % (w/w); mangiferin 
was identified as the major flavonoid in the extract by thin 
layer chromatography (TLC) with mobile phase methanol-
acetate-water (9:0.5:0.5). TLC demonstrated a mangiferin 
spot in the extract at the same Rf and with the same 
reaction as pure mangiferin (Rf 0.86). Semiquantitative 
TLC determination confirmed the mangiferin content in 
the leaf extract of about 1% (20).
Experimental animals and study design 
Thirty male Sprague Dawley rats were randomly divided 
into 5 equal groups: normal group (N), the group of iron 
overload without therapy as negative control (IO), the 
group of iron overload that received DFP as the positive 
control (IO + DFP), mangiferin 75 mg / kg (IO + M), and 
EMF (IO + EMF). Induction of iron overload was achieved 
by intraperitoneal (IP) injection of 0.3 mL iron dextran 
containing 15 mg Fe, twice a week for 3 weeks. After 3 
weeks of iron overloading, therapy followed orally for 7 
days (week 4) with DFP, mangiferin, or EMF, respectively 
(Table 1).
Blood was taken from the orbital sinus 3 times during 
Table 1. Study design: treatment of animals
Groups
Weeks 1, 2, and 3 Week 4 Sacrificed after 4 
weeksDay 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
N = C - - - - - - - - - - - - - - X
IO • - - • - - - - - - - - - - X
IO+DFP • - - • - - - ◊ ◊ ◊ ◊ ◊ ◊ ◊ X
IO+M • - - • - - - □ □ □ □ □ □ □ X
IO+EMF • - - • - - - ♣ ♣ ♣ ♣ ♣ ♣ ♣ X
Note: N= normal control; IO= iron overload 90 mg IP/ kg BW (negative control); IO+DFP = iron overload + deferiprone 75 mg/kg BW (positive control); 
IO+M= iron overload + mangiferin 75 mg/kg BW; IO+EMF = iron overload + Mangifera foetida leaf extract 2930 mg/kg BWequivalent to mangiferin 
75 mg/kg BW; • = administration of iron dextran; ◊= administration of deferiprone; □ = administration of mangiferin; ♣= administration of Mangifera 
foetida leaf extract.
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the study, at the beginning of the study, after 3 weeks 
(induction of iron overload), and after therapy (week 
4). Urine was collected twice, after 3 weeks and after 
therapy (week 4). Iron levels were determined from blood 
and urine, superoxide dismutase (SOD) activity and 
malondialdehyde (MDA) levels only from blood. 
During the four weeks of the experiment, the rats 
were treated according to prevailing standards and 
monitored daily and noted signs of general toxicity such 
as weight loss, diarrhea and death. The animals were kept 
according to the Helsinki and Tokyo Declarations in their 
updated international version of year 2000 and European 
Directives for Animal Experiments (1986/609/EEC and 
2010/63/EU).
Assay of total iron in plasma and urine
Measurement of the iron concentration in plasma and 
urine referred to publications by Rodríguez et al (17) and 
Papanasstosiou et al (21) with slight modifications based 
on preliminary tests conducted prior to the main study. 
Plasma samples (100 µL) or urine (300 µL) were destroyed 
with 1 mL conc. HNO3/HClO4 (2:1) and then diluted 
with distilled water to a volume of 5 mL. Subsequently, 
measurement was done with AAS in BGC-D2 lamp mode 
at a wavelength of λ 248.3 nm.
Determination of SOD activity in blood
SOD activity was determined according to the method 
Misra and Fridovich (22). Samples of blood homogenate 
of 250 mL to 400 mL of solution mixture was added 
chloroform-ethanol (3:5), then centrifuged at 3000 rpm 
for 10 minutes. Light yellow filtrate taken 10 µL clear then 
added 90 µL aquabidest and 2775 µL carbonate buffer 
0.0518 M and 125 µL epinephrine solution 0.01 M. 
The absorbance of this mixture was measured after 1, 2, 3 
and 4 minutes at a wavelength of 480 nm and temperature 
of 37ºC. SOD activity in blood was calculated as inhibition 
of epinephrine oxidation, 50% inhibition being equivalent 
to 1U og SOD (or “SOD-like”) activity.
MDA determination with the TBA method
Examination of lipid peroxidation by using MDA 
measurement was done according to the method of Wills 
modified by Devasagayam et al (23). To the samples or 
standards in the form of plasma MDA 200 µL plus 1800 
µL of distilled water, 1 mL TCA 20% and 2 mL TBA 0.67% 
were added and mixed homogeneously. The mixture was 
measured with a spectrophotometer at a wavelength of 
530 nm.
Data processing and statistical analysis 
The results obtained in the form of numerical data 
comparing the results of more than two groups were 
statistically analyzed by one-way ANOVA parametric test 
for normal distribution and homogeneous variance. Limit 
of significance was set to P = 0.05. To compare two groups, 
post hoc multiple comparison test LSD followed. If the 
above ANOVA hypothesis did not qualify, Kruskal-Wallis 
test followed by post hoc Mann-Whitney was applied.
Results
Body weight
Between the first and the 25th day, all groups gained 
weight (28-51 g), except for the iron-overloaded group 
(IO), which had a slight weight loss. 
Plasma iron concentration
The difference in plasma iron between 3 and 4 weeks of 
the experimental course was calculated from the values 
in Table 2. In normal controls the difference in iron 
concentration was +1.22±0.57 µg/mL (slight increase), 
in the IO group the difference in iron concentration was 
-15.0814.78 µg/mL (slight decrease), whereas the decrease 
was significant in all therapy groups: 261.92±183.20 µg 
Fe/mL in IO+DFP, 217.08±198.79 µg Fe/mL in IO+M, 
and 168.20±166.24 µg Fe/mL in IO+EMF.
Iron excretion via urine
To evaluate the effect of the therapies, the differences 
of iron excretion in urine between 3 and 4 weeks of the 
experimental course were calculated from the values in 
Table 2. In normal controls, there was no difference. In 
the IO group, iron excretion increased by 2.83±1.64 µg/
mL, in the IO+DFP group, iron excretion increased by 
39.27±6.71 µg/mL, in the IO+M group by 12.30±5.48 µg/
mL, and in the IO+EMF group by 3.99±1.93 µg/mL.
MDA plasma concentration
After 3 weeks, MDA was 0.908±0.23 nmol/mL in normal 
controls and increased significantly (P = 0.018) in all iron 
overloaded groups to a range between 4.17 and 5.71 nmol/
mL without significant differences between these groups 
(p = 0.327). After 4 weeks and treatment of the IO+DFP, 
IO+M, and IO+EMF groups, MDA was 0.726±0.16 nmol/
mL in normal controls and between 1.21 and 1.49 nmol/
mL in all iron-overloaded groups without any significant 
differences before and after treatments and between all 
groups (Figure 1).
Iron overload increased MDA significantly 4- to 
5-fold, which was the only significant result in MDA 
measurements. Treatment with iron-chelators decreased 
MDA generation, but the IO group without any therapeutic 
treatment exhibited the same effect. Differences between 
all these groups were not significant.
SOD activity in blood
SOD activity in plasma was measured as inhibition of 
epinephrine oxidation. We determined epinephrine 
oxidation in plasma after 3 weeks and after 4 weeks in our 
experimental design. Then, we calculated the difference in 
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arbitrary units (Figure 2). Mangiferin and the extract from 
mango leaves exert higher SOD-like activities than DFP. 
Discussion
Until now, thalassemia is incurable. Management is a 
supportive therapy for patients with transfusion of blood 
on a regular basis to maintain hemoglobin levels of about 
9-10 g/dL. However, regular blood transfusions in these 
patients increase endogenous iron levels. Currently, the 
average age of patients with thalassemia major can reach 3 
decades, and generally patients die from an excess of iron 
in the myocardium (5). 
To overcome the accumulation of excess iron (iron 
overload) iron chelating agents are administered to 
excrete excess iron from the body and to slow down the 
accumulation of Fe in tissues (11,12). We used DFP as 
positive control, because it can be administered orally, i.e., 
via the same route as mangiferin or EMF. Iron chelation 
therapy must be given lifelong. Unfortunately, the drugs 
available in the market are still imported, so the costs 
Table 2. Total Fe concentration in plasma and excretion in urine
Parameter Normal control (C)
IO = Iron 
overload
IO + DFP 
(deferiprone)
IO + M 
(mangiferin)
IO + EMF (M. f. 
leaf extract)  
Significance
(P < 0.05)
Body weight
Day 1 196.67±25.48 235.67±14.11 212.33±24.64 220.33±23.34 203.00±21.31
Not significant
Day 25 246.67±13.66 229.00±40.37 263.83±24.33 268.33±21.13 231.83±52.00
Total plasma iron concentration (µg/mL)
After 3 weeks = before 
therapy
1.46±0.56 315.46±233.23 371.49±253.62 363.58±289.84 317.65±280.73
After 4 weeks = after 
therapy
0.242±0.11 300.38±266.52 109.57±70.69 146.50±141.33 154.85±134.47
Difference of plasma iron concentration (µg/mL), before and after therapy 
# significant to C group, 
*significant to IO group
Fe plasma +1.22±0.57 -15.08±14.78
-261.92±183.20
# (P=0.000)
* (P=0.000)
-217.08±198.79
#(P=0.000) 
*(P=0.001)
-168.20±166.24
# (P=0.000)
* (P=0.003)
Iron excretion via urine [µg Fe/mL urine]
After 3 weeks = before 
therapy
0.01±0.00 2.87±0.66 2.23±0.71 3.15±0.80 4.19±1.84
After 4 weeks = after 
therapy
0.01±0.00 5.70±1.26 41.50±6.67 15.46±5.10 8.18±1.94
Difference of  iron excretion via urine [ug/mL], before and after therapy # significant to C group,
*significant to IO group
**significant to IO+DFP 
group
***significant to IO+M 
group
Fe in urine 0.00 ±0.00 +2.83±1.64
+39.27±6.71
# (P=0.000) 
*(P=0.000)
+12.30±5.48
#(P=0.000) 
*(P=0.000)
**(P=0.000)
+3.99±1.93
#(P=0.000)
**(P=0.000)
***(P=0.000)
% Inhibition epinephrine oxidation in plasma = SOD activity [U/mL]
After 4 weeks 1.49 ± 0.24 0 0.81 ± 0.24 1.29 ± 0.30 1.47 ± 0.34 Not significant
Note: N= normal control; IO= iron overload 90 mg IP/ kg BW (negative control); IO+DFP = iron overload + deferiprone 75 mg/kg BW (positive control); 
IO+M= iron overload + mangiferin 75 mg/kg BW; IO+EMF = iron overload + Mangifera foetida leaf extract 2930 mg/kg BWequivalent to mangiferin 75 
mg/kg BW.
Figure 1. Mean of malondialdehyde (MDA) concentration among groups before and after treatment with error bars SD, P = 0.327
Note: N = normal control, IO = iron overload, no treatment as negative control, IO+DFP = iron overload + treatment deferiprone 75 mg/kg BW as 
positive control, IO+M = iron overload + mangiferin 75 mg/kg BW, IO+EMf = iron overload + Mangifera foetida leaf water extract. *P < 0.05 compare 
to N group .
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are very high. This is a burden for the patients and their 
families and for the government. Seeing these problems, we 
need to consider alternative drugs derived from domestic 
sources. Mangiferin is a polyphenolic antioxidant that has 
been found in and extracted from M. indica L. 
This study showed that intraperitoneal administration 
of iron twice a week for 3 weeks with total amount of 90 
mg iron increased plasma iron levels more than 200-fold 
as compared to controls and could serve as an animal 
model for iron overload. This method was developed from 
Papanastasiou et al (25). Intraperitoneal administration 
was chosen because it was easier and increased iron levels 
faster than oral administration.
After 3 weeks of excessive iron administration, it showed 
that DFP administration for 7 days could decrease plasma 
iron level by 70%, while administration of mangiferin and 
Mangifera foetida extract could decrease plasma iron level 
by 60% and 50%, respectively. The results showed that 
mangiferin could reduce plasma iron levels even though 
not as much as DFP. It proves that mangiferin has an iron-
chelating effect and can excrete iron from the body. This 
result corresponds to in vitro studies by Andreau et al 
(15), which proved that mangiferin could bind free iron. 
The administration of Mangifera foetida leaf extract also 
showed similar effect, because it contains mangiferin. 
The decrease in iron plasma levels in the therapy groups 
is proportional to the increase in iron excretion in the 
urine. In this study, the levels of Fe in urine in the fourth 
week was about 15-fold in the positive control (IO+DFP), 
about five-fold in the IO+mangiferin group, and two-fold 
in the IO+EMF group. In other words, mangiferin and the 
extract from Mango leaves increased iron excretion via 
urine, but not as strong as DFP. 
 In vitro tests with mangiferin have proven activity as 
iron chelator and as antioxidant, which was considered 
“SOD-like” activity (26,27). This latter activity is not 
generally seen with iron chelators, especially not with 
deferoxamin or DFP. Pardo-Andreau et al (28,29) have 
proven that mangiferin can form complexes with Fe 
(III). Such complexes can prevent the formation of and 
scavenge free radicals, thereby enhancing the effectiveness 
of mangiferin as antioxidant (28,29). 
In its antioxidant capacity, EMF was even more 
potent than purified mangiferin. This is certainly due to 
additional antioxidants contained in the EMF (30). 
After 3 weeks, iron overload increased MDA 
significantly 4- to 5-fold. Treatment with iron-chelators 
decreased MDA generation, but the IO group without 
any therapeutic treatment exhibited the same effect. 
Thus, there are no differences between the iron-
overloaded groups. In other words, in the fourth week, 
lipid peroxidation decreased, because administration of 
excessive iron was discontinued, no matter whether rats 
obtained iron chelators or not. 
 SOD activity in plasma was measured as inhibition 
of epinephrine oxidation. It has been discussed in 
literature and questioned whether this assay is suitable 
for determination in biological systems. The strongest 
antioxidant effect was observed with the Mango leaves 
extract, even slightly higher than by mangiferin alone. 
This may be due to other antioxidant components in 
the leaf extract, which contribute to the total antioxidant 
activity. 
Conclusion
From the experiments with iron-overloaded rats we 
conclude that mangiferin and mangiferin-containing 
extracts from M. foetida leaves (EMF) are potent candidates 
as antioxidant iron chelators in the management of iron-
overloaded thalassemia patients. 
Further investigations are necessary to assay the 
pharmacokinetics of mangiferin with varying dosage and 
pharmaceutical preparation procedures, before we can 
recommend mangiferin to humans. 
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